The Kiran Infertility Centre- KIC is a Super Specialty Facility dealing in Infertility Treatments & Surrogacy. An ISO 9001- 2008 Company, KIC with its cutting-edge technology, world-renowned experts and a patient-centric approach, has been a dominant player in the area of Fertility Treatments and is one of the oldest facilities in India offering Infertility Treatment. Dr Pratima Grover
Joerns Healthcare has launched the Dolphin Fluid Immersion Simulation® system that more effectively prevents and treats pressure-related injuries than other surfaces. This patented technology simulates the effect of floating in water for patients on hospital beds, stretchers, and in wheel chairs. The Dolphin technology continually adjusts to the patient’s body, promoting tissue perfusion and oxygenation, and minimizing injury related to compromised blood flow. The Dolphin is also proven to accelerate healing of advanced stage or multiple pressure ulcers, muscle flaps, skin grafts, burns and other wound conditions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58463-joerns-dolphin-fluid-immersion-simulation-system-pressure-related-injuries
Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) presented today at a symposium during the World Diabetes Congress of the International Diabetes Federation (IDF), show that only 29% of people with diabetes report that their healthcare team ask for their input when making their treatment plans. Furthermore, only 33% said they were encouraged by their healthcare professional to ask questions in the consultation.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64152-novo-nordisk-diabetes-report-doctor-treatment
Close-Up TV News recognizes Diamond Dental Care for its commitment to quality patient care.
Servicing its community for over 30 years, Diamond Dental Care is a family owned and operated dental practice specializing in the full spectrum of lifelong dental care. Lead by Dr. Fred Turner, Diamond Dental Care’s goal is for each patient to leave with their best smile possible through durable, functional and clinically sound treatments that also provide aesthetically pleasing and natural results.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/diamonddental/45801/
Today’s U.S. healthcare providers face a three-pronged deluge of demands from patients, insurance companies, and the government. To successfully address these new and evolving expectations, members of the medical sector must leverage the capabilities of new wireless technologies – or fall behind their more savvy competitors.
Frost & Sullivan recently published a whitepaper, Mobile Devices and Healthcare: What’s New, What Fits, and How Do You Decide?, which examines the strengths and drawbacks of four major mobile device types – smartphones, tablets, push-to-talk communication devices, and machine-to-machine (M2M) remote medical monitoring devices. Each device category is evaluated for application in three unique environments – the hospital, physician’s office, and the patient’s home. Criteria for selecting a mobility partner are also discussed.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/51532/
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
Cutanea Life Sciences, Inc. (CLS), an emerging U.S. prescription product development company, formally unveiled its new digital presence, www.cutanea.com, to the dermatology community in conjunction with this winter’s annual gathering of dermatologists from the U.S and around the world. CLS has a stream of innovative product candidates in different stages of development that cover an array of skin conditions, including acne, rosacea, psoriasis and warts caused by human papillomavirus (HPV).
CLS’s new digital presence demonstrates the company’s intent to change the way that customers think about a valued dermatology partner. CLS believes that it can make an impact in the current state of dermatology practice through its commitment to focus on unmet and underserved patient needs. In turn this will help medical professionals optimize their practice time through CLS products and services.
To view the multimedia release go to:
http://www.multivu.com/players/English/7743651-cutanea-life-sciences-dermatology/
Ascensia Diabetes Care today announced the availability of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in the United Kingdom, one of the next steps in the evolution of self-monitoring of blood glucose. As part of the system, the CONTOUR®NEXT ONE meter and CONTOUR®DIABETES app seamlessly connect, which makes capturing blood glucose results effortless for people with diabetes. The system enables patterns and trends to be revealed that can help people understand their diabetes, and may help to improve diabetes management.
The system features an easy-to-use wireless-enabled smart meter that links to a smart mobile device via Bluetooth® connectivity. The CONTOUR®NEXT ONE meter gives immediate feedback and also seamlessly connects to the CONTOUR®DIABETES app, which collects, stores and analyses patient blood glucose results received from the meter. The app combines these results with other data recorded by the user, to provide detailed information about their condition that can help them understand how their everyday lives may impact their blood glucose readings, including alerts for critical high or critical low readings. Through the app, meter users can also share with their healthcare professional the reports of their blood glucose results and patterns, either in advance or on the day of their appointment, helping to create more informed discussions.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7954951-contour-next-one-bgms-ascensia/
New research released today to mark European Week Against Pain reveals that, in more than half of cases, peoples’ levels of pain across Europe are not being adequately assessed.
More than half (52%) of European primary care physicians use no form of assessment tool to measure peoples’ levels of pain despite chronic pain affecting 1 in 52 adults across Europe. A study in Finland found that pain is also the reason for 40% of patient visits to a primary care physician each year, with approximately 20% of these patients having experienced their pain for more than 6 months.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/mundipharma/52140/
Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or “double chin.” And with social media profile images becoming more important than ever, there is interest in looking one’s best.
Submental fullness due to fat beneath the chin can impact a broad range of both men and women and because the condition can be genetic and resistant to diet and exercise. But there’s KYBELLA®, the first and only FDA-approved injectable treatment that is available by prescription only, that has been proven to improve the appearance of moderate to severe fat beneath the chin by physically destroying fat cells in the treatment area. In two pivotal clinical studies for KYBELLA®, reductions in submental fat volume were observed more frequently in the KYBELLA® treated group of 514 patients compared to the placebo group (508 patients) as measured by both clinician and patient ratings. In addition, visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were evaluated using a 6-question survey and 79% of 1 and 2-grade composite responders reported satisfaction after 12 weeks post final treatment compared with 33.6% of patients who received placebo.
To view the multimedia release go to:
http://www.multivu.com/players/English/7962051-kybella-injectable-double-chin-treatment-campaign/
The Center For Aesthetics
https://thecenterforaesthetics.com
800-575-8337 ~ Patient 'Beautiful Journey' Stories - Serpahim.
CFA Beauty the premier aesthetic medical centers in Scottsdale, Jackson Hole, Idaho Falls.
The Center For Aesthetics
https://thecenterforaesthetics.com ~ 800-575-8337 ~ Patient 'Beautiful Journey' Stories - Tanya. CFA Beauty the premier aesthetic medical centers in Scottsdale, Jackson Hole, Idaho Falls.
